Clearance of anti-double-stranded DNA antibodies: The natural immune complex clearance mechanism

Arthritis and Rheumatism

Volumn 43, Issue 10, 2000, Pages 2265-2275

  Craig, Maria L ^a   Bankovich, Alexander J ^a   McElhenny, Jennifer L ^a   Taylor, Ronald P ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; COMPLEMENT RECEPTOR; DNA ANTIBODY; FC RECEPTOR;

ANTIBODY DETECTION; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CELL STRAIN U937; CONTROLLED STUDY; ERYTHROCYTE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIVER; PHAGOCYTE; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, ANTINUCLEAR; ANTIGEN-ANTIBODY COMPLEX; AUTOIMMUNE DISEASES; DNA; ERYTHROCYTES; HUMANS; IMMUNOGLOBULIN G; LUPUS ERYTHEMATOSUS, SYSTEMIC; METALLOENDOPEPTIDASES; MICE; PHAGOCYTES; RECEPTORS, COMPLEMENT 3B; U937 CELLS;

EID: 0033791704     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200010)43:10<2265::AID-ANR14>3.0.CO;2-J     Document Type: Article

References (65)

1. Primate erythrocyte-immune complex-clearing mechanism
2. The erythrocyte-immune complex-glomerulonephritis connection in man
3. Physiological and pathological aspects of circulating immune complexes
4. Bispecific monoclonal antibody complexes facilitate erythrocyte binding and liver clearance of a prototype particulate pathogen in a monkey model
5. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte
6. The immune-adherence phenomenon: An immunologically specific reaction between microorganisms and erythrocytes leading to enhanced phagocytosis
7. The immune-adherence phenomenon: A hypothetical role of erythrocytes in defence against bacteria and viruses
8. Immune adherence
9. In vivo in vitro studies of the binding of antibody/dsDNA immune complexes to rabbit and guinea pig platelets
10. C1q and C4b bind simultaneously to CR1 and additively support erythrocyte adhesion
11. How are immune complexes bound to the primate erythrocyte complement receptor transferred to acceptor phagocytic cells?
12. Bispecific monoclonal antibody complexes bound to primate erythrocyte complement receptor 1 facilitate virus clearance in a monkey model
13. Human complement receptors for C3b (CR1) and C3d (CR2)
14. Rapid immune adherence reactivity of nascent, soluble antibody/DNA immune complexes in the circulation
15. A study of in vivo immune complex formation and clearance in man
16. Immune complex processing in patients with systemic lupus erythematosus
17. Mechanism of transfer of immune complexes from red blood cell CR1 to monocytes
18. Quantitative analyses of the relationship between C3 consumption, C3b capture and immune adherence of complement-fixing antibody/DNA immune complexes
19. Deoxyribonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus
20. Immunology of DNA. V. Analysis of DNA/anti-DNA complexes
21. Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus
22. Reassessment of the clinical significance of native DNA antibodies in systemic lupus erythematosus
23. Antibodies to DNA: A perspective
24. The interaction of antibody/DNA immune complexes with complement: Influence of antibody class and DNA conformation
25. Immune complexes in systemic lupus erythematosus
26. The origin, sequence, structure, and consequences of developing anti-DNA antibodies: A human perspective
27. Suppression of murine lupus nephritis by administration of an anti-idiotypic antibody to anti-DNA
28. Randomised trial of plasma exchange in mild systemic lupus erythematosus
29. Selective removal of anti-DNA and anticardiolipin antibodies by adsorbent plasmapheresis using dextran sulfate columns in patients with systemic lupus erythematosus
30. Use of heteropolymeric monoclonal antibodies to attach antigens to the C3b receptor of human erythrocytes: A potential therapeutic treatment
31. Antigen-based heteropolymers: A potential therapy for binding and clearing autoantibodies via erythrocyte CR1
32. Antigen-based heteropolymers facilitate, via primate erythrocyte complement receptor type 1, rapid erythrocyte binding of an autoantibody and its clearance from the circulation in rhesus monkeys
33. Primate erythrocyte (E) complement receptor (CR1) as an anchor site for bispecific-based therapies to clear pathogens or autoantibodies safely from the circulation
34. Immune complexes bound to the primate erythrocyte complement receptor (CR1) via anti-CR1 mabs are cleared simultaneously with loss of CR1 in a concerted reaction in a rhesus monkey model
35. Complement-opsonized IgG antibody/dsDNA immune complexes bind to CR1 clusters on isolated human erythrocytes
36. Stability of DNA/anti-DNA complexes. III. Kinetic control of immune complex size
37. Use of maleimidethiol coupling chemistry for efficient syntheses of oligonucleotide-enzyme conjugate hybridization probes
38. Infusion of bispecific monoclonal antibody complexes into monkeys provides immunologic protection against later challenge with a model pathogen
39. Stability of DNA/anti-DNA complexes. IV. Complement fixation
40. Functional characterization of non-human primate erythrocyte immune adherence receptors: Implications for the uptake of immune complexes by the cells of the mononuclear phagocytic system
41. Quantitative analyses of the binding of soluble complement-fixing antibody/dsDNA immune complexes to CR1 on human red blood cells
42. Relevance of L-selectin shedding for leukocyte rolling in vivo
43. Establishment and characterization of a human histiocytic lymphoma cell line (U-937)
44. Direct evidence of the clustered nature of complement receptors type 1 on the erythrocyte membrane
45. Distribution in clusters of complement receptor type one (CR1) on human erythrocytes
46. The human mononuclear phagocyte high-affinity Fc receptor, FcRI, defined by a monoclonal antibody, 10.1
47. Human monocytes and U937 cells bear two distinct Fc receptors for IgG
48. Alveolar and peritoneal macrophages bear three distinct classes of Fc receptors for IgG
49. Mapping epitopes for 20 monoclonal antibodies to CR1
50. In vivo handling of soluble complement fixing Ab/dsDNA immune complexes in chimpanzees
51. Cross-linked bispecific monoclonal antibody heteropolymers facilitate the clearance of human IgM from the circulation of squirrel monkeys
52. Complement receptor (CR1) deficiency in erythrocytes from patients with systemic lupus erythematosus
53. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation
54. Altered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual men: Varying risk groups for acquired immune deficiency syndrome
55. Receptors for immunoglobulin G: Molecular diversity and implications for disease
56. Myeloid cell-targeted cytotoxicity of tumor cells
57. Membrane complement receptors specific for bound fragments of C3
58. Binding of model immune complexes to erythrocyte CR1 facilitates immune complex uptake by U937 cells
59. Involvement of a metalloprotease in spontaneous and phorbol ester-induced release of natural killer cell-associated FcRIII (CD16-II)
60. Inhibitors of metalloproteases
61. Transfer of immune complexes from erythrocyte CR1 to mouse macrophages
62. Release of vesicles enriched in complement receptor 1 from human erythrocytes
63. Catabolism of the human erythrocyte C3b/C4b receptor (CR1, CD45): Vesiculation and/or proteolysis
64. Cytotoxicity mediated by human Fc receptors for IgG
65. The binding and processing of monoclonal human IgG1 by cells of a human macrophage-like cell line (U937)